Pons, Laura
Hernández-León, Laura
Altaleb, Ahmad
Ussene, Esperança
Iglesias, Roman
Castillo, Ana
Rodríguez-Martínez, Paula
Castella, Eva
Quiroga, Vanesa
Felip, Eudald
Cirauqui, Beatriz
Margelí, Mireia
Fernández, Pedro Luis
Funding for this research was provided by:
Instituto de Salud Carlos III (PI 19/01371)
Fundació la Marató de TV3
Article History
Received: 25 January 2022
Accepted: 15 April 2022
First Online: 17 May 2022
Competing interests
: M. Margelí reports advisor role or consulting from Novartis, Pfizer, Roche; research funding from Roche, Eisai, Astrazeneca; travel expenses from Roche. PL Fernandez declares travel expenses from Roche. All other authors declare no competing interests.